ストックスクリーナーアプリを入手
18.97
4.39%
-0.87
アフターアワーズ：
18.97
Zenas Biopharma Inc (ZBIO) 最新ニュース
ZBIO INVESTOR ALERT: Zenas BioPharma, Inc. Investors with Substa - GuruFocus
Zenas BioPharma to present obexelimab trial data at EULAR congress - Investing.com UK
Zenas BioPharma to present obexelimab trial data at EULAR congress By Investing.com - Investing.com Nigeria
Why is Zenas Biopharma stock climbing today? By Investing.com - Investing.com Australia
Zenas BioPharma To Present INDIGO Phase 3 Data At EULAR 2026; Wedbush Sees $45 Target - RTTNews
Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress - The Manila Times
Obexelimab cuts IgG4-RD flare risk 56%, results to be presented at EULAR 2026 - Stock Titan
Zenas BioPharma Insider Bought Shares Worth $1,012,800, According to a Recent SEC Filing - Moomoo
Zenas BioPharma CEO Leon Moulder Jr purchases $1.01m in common stock By Investing.com - Investing.com South Africa
Zenas BioPharma CEO Leon Moulder Jr purchases $1.01m in common stock - Investing.com Australia
Zenas BioPharma (ZBIO) CEO adds 60,000 shares in open-market buy - Stock Titan
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New hires at Zenas BioPharma get 51,075 stock units over 4 years - Stock Titan
Zenas BioPharma Advances Phase 3 Orelabrutinib Trial in Tough MS Segment - TipRanks
Zenas BioPharma rises as CEO continues insider purchases - MSN
Assessing Zenas BioPharma (ZBIO) Valuation After Obexelimab Phase 3 Success And New IL-17 Program Progress - Sahm
Vanguard Group Inc. Acquires 290,307 Shares of Zenas BioPharma, Inc. $ZBIO - MarketBeat
ZBIO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $44 - GuruFocus
H.C. Wainwright Maintains Zenas BioPharma(ZBIO.US) With Buy Rating, Maintains Target Price $44 - Moomoo
Citi opens ‘upside 30-day catalyst watch’ on Zenas BioPharma - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Morgan Stanley Maintains Zenas BioPharma(ZBIO.US) With Hold Rating, Raises Target Price to $22 - Moomoo
How Zenas BioPharma’s First-in-Human Oral IL-17 Trial Could Reframe Zenas BioPharma (ZBIO) Investors - Sahm
ZBIO SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Zenas BioPharma Releases Q1 2026 Financial Results - AlphaStreet
Why Zenas BioPharma (ZBIO) Is Down 7.7% After Reporting a Sharply Wider Quarterly Net Loss - Yahoo Finance
Zenas BioPharma 4Q Loss/Shr $1.46 >ZBIO - Moomoo
Zenas BioPharma, Inc. 2026 Q1 Financial Report: Forward-Looking Statements, Risk Factors, and Management Discussion - Minichart
Zenas BioPharma doses first patient in Phase 1 clinical trial of ZB021 - TipRanks
Zenas BioPharma doses first patient in ZB021 phase 1 trial By Investing.com - Investing.com Nigeria
Zenas BioPharma doses first patient in ZB021 phase 1 trial - Investing.com
Zenas BioPharma Reports Q1 2026 Results: Obexelimab Nears FDA Submission for IgG4-RD, Pipeline Advances, and Cash Runway Extended to 2029 1245 - Minichart
Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor - The Manila Times
Zenas Biopharma Announces First Subject Dosed In Phase 1 Clinical Trial Of Zb021, A Novel, Potentially Best-In-Class Oral Il-17Aa/Af Inhibitor - TradingView
Zenas BioPharma (Nasdaq: ZBIO) doubles cash while quarterly loss widens - Stock Titan
Zenas BioPharma reports Q1 EPS ($1.46) vs. (80c) last year - TipRanks
Zenas BioPharma Highlights Strong Q1 Progress and Financing - TipRanks
Zenas BioPharma, Inc. 1Q 2026: Revenue $16.91M, EPS ($1.46) — 10-Q Summary - TradingView
Zenas BioPharma (NASDAQ: ZBIO) widens loss but lifts cash to $718.5M - Stock Titan
Tomas Kiselak resigns from Zenas BioPharma board after term expiration - TradingView
Zenas BioPharma Q1 Net Loss Widens - Moomoo
Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Earnings Flash (ZBIO) Zenas BioPharma Posts Q1 Net Loss $1.46 a Share, vs. FactSet Est of $1.47 Loss - marketscreener.com
Zenas BioPharma Reports Progress on Obexelimab and ZB021 Trials, Financial Milestones and Upcoming Regulatory Submissions - Quiver Quantitative
Earnings Flash (ZBIO) Zenas BioPharma Posts Q1 Net Loss $1.46 a Share, Vs. FactSet Est of $1.47 Loss - Moomoo
TradingKey - TradingKey
Number of shareholders of Zenas BioPharma, Inc. – NASDAQ:ZBIO - TradingView
Alpha Buying: Insider Conviction in High-Risk Biotech - Sahm
Zenas BioPharma (ZBIO) CEO and entities report 3,220,880 shares owned - Stock Titan
2.98%
1.33%
大文字化:
|
ボリューム (24 時間):